The GLP is committed to full transparency. Download and review our 2019 Annual Report

Immunotherapy can provide ‘spectacular results’. But how effective is it for the elderly?

| | July 9, 2018
alzheimers b
Image credit: Alamy
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Immunotherapy is effective against a variety of cancers, with sometimes spectacular results. But I worry about how effective it is in people over age 65, who make up half of cancer patients.

We know that immunotherapy is tolerated by older individuals. But how well they respond to it and the side effects it causes them may be different from those observed in most clinical studies for two reasons. One is that clinical trials tend to include younger participants. The other is because of an aging process known as immunosenescence. It causes the immune system to change and become less effective over time.

But we don’t know as much as we should about immunotherapy for older individuals as they are poorly represented in clinical trials. In 2013, individuals between the ages of 65 and 69 years made up 17 percent of clinical trial participants, those between the ages of 75 and 79 years made up 8 percent, and those who were 80 years and older made up only 4 percent.

Related article:  Video: Why infectious diseases are so troublesome for air travelers

To help everyone — physicians, researchers, and patients — better understand how the immune system changes with age and how those changes could influence the success of immunotherapy, future studies must include a more representative elderly population, including those with multiple health issues.

Read full, original post: We need more answers about immunotherapy for the elderly

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend